A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors
Status:
COMPLETED
Trial end date:
2025-04-30
Target enrollment:
Participant gender:
Summary
This is a FIH, ascending dose study to characterize the safety, tolerability, optimal dose and preliminary anti-tumor activity of IMM-6-415 in participants with advanced or metastatic solid tumors harboring RAS or RAF oncogenic mutations.